Beauty Health Co. Files 8-K Report

TL;DR

Beauty Health Co. filed an 8-K on Sept 4, 2025, for material agreements & financials. Details TBD.

AI Summary

On September 4, 2025, Beauty Health Co. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the submission of financial statements and exhibits. No specific details regarding the agreement or financial figures were provided in the excerpt.

Why It Matters

This 8-K filing indicates significant corporate activity, potentially involving new agreements or financial disclosures that could impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for material definitive agreements and financial statements, with no immediate negative or positive indicators presented in the provided text.

Key Players & Entities

• Beauty Health Co. (company) — Registrant
• September 4, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-39565 (filing_id) — Commission File Number
• 85-1908962 (ein) — IRS Employer Identification No.
• 2165 Spring Street (address) — Principal executive offices street
• Long Beach (city) — Principal executive offices city
• CA (state) — Principal executive offices state
• 90806 (zip_code) — Principal executive offices zip code
• (800) 603-4996 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Mar

Filing Documents

• skin_8k.htm (8-K) — 27KB
• skin_ex0401.htm (EX-4.1) — 59KB
• 0001683168-25-006690.txt ( ) — 259KB
• skin-20250904.xsd (EX-101.SCH) — 3KB
• skin-20250904_lab.xml (EX-101.LAB) — 33KB
• skin-20250904_pre.xml (EX-101.PRE) — 22KB
• skin_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On September 4, 2025, The Beauty Health Company (the "Company"), certain domestic subsidiaries of the Company (the "Existing Guarantors") and certain foreign subsidiaries of the Company (the "New Guarantors") entered into Supplemental Indenture No.1 (the "Supplemental Indenture") with U.S. Bank Trust Company, National Association, as trustee (the "Trustee") and collateral agent (the "Collateral Agent"). The Supplemental Indenture modified that certain indenture (the "Indenture"), dated as of May 27, 2025, among the Company, the Existing Guarantors, the Trustee and the Collateral Agent, related to the Company's 7.95% Convertible Senior Notes due 2028 (the "Notes"), to (i) provide for the guarantee of the Notes by the New Guarantors, which are secured on a first-priority basis by substantially all assets of such guarantors, subject to certain exceptions, and (ii) cure certain ambiguities, omissions, defects and inconsistencies in the Indenture. The foregoing description of the Supplemental Indenture is a summary and is not complete. A copy of the Form of Supplemental Indenture is attached as Exhibit 4.1 to this Current Report on Form 8-K (the " Current Report ") and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Supplemental Indenture No. 1, dated September 4, 2025, among The Beauty Health Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent . 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 4, 2025 The Beauty Health Company /s/ Michael Monahan Michael Monahan Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR